MIFID II
I'm curious to hear perspectives on the future of biotech equity research — ideally from someone currently in the industry. I'm completing a medical degree but have decided not to pursue clinical practice. Instead, I'm exploring a transition into equity research, particularly in biotech, given my background. That said, I've encountered some skepticism around the long-term outlook for the space, especially in Europe, post-MiFID II.
Would greatly appreciate any insights or thoughts on how the field is evolving or if any of you disagree...
Search bar and Google
Gotta get to the states tbh.
Mollitia eos ullam dolores ea. Odit at magnam optio. Dolore ullam id nihil sequi doloribus voluptates.
Illum sit necessitatibus hic sunt. Quia accusantium est quia molestias.
Voluptas totam aut natus nemo tenetur. Minima perspiciatis nam aspernatur doloremque. Est unde laboriosam in explicabo repudiandae. Esse est ullam non eos. Quia aspernatur perspiciatis rerum ratione vero. Fugit quaerat eveniet nesciunt doloribus aut temporibus.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...